3rd April 2020
NovaMechanics offers state-of-the-art research tools to support industry in navigating the drug discovery process towards a COVID-19 cure.
NovaMechanics Ltd is a unique drug design and discovery contract research organisation. It provides bespoke in silico drug design and discovery products and services centred around high throughput computational techniques.
The company applies state-of-the-art machine learning and artificial intelligence techniques, for the interpretation and implementation of validated predictive models to big data analysis, personalised medicine, clinical trials, computer-aided drug discovery and material science. The aim is to increase profitability, decrease risk, and reduce experimental cost by conceiving new modelling ideas and devising the simulations needed to test them.
NovaMechanics’ custom made in silico models and simulation tools are dedicated to the interpretation of research results and to the design of effective experiments in order to validate them. Their proprietary algorithms can rapidly convert ligand information or protein structure information into new chemical designs, maximising the value within the research portfolio of a pharmaceutical partner.
NovaMechanics is offering the use of its products and services to the drug discovery industry during the COVID-19 pandemic.
ASK: Research contributors needed for CON-VICE study
University of Luxembourg needs European researchers to get in touch
OFFER: Funding available for COVID-19 research
Fondation Air Liquide are looking to fund European projects
ASK: Supporting the immunocompromised
Partners sought to advance neutralising antibody